MD4430C1 - Compoziţii şi metode de tratament al hepatitei virale C - Google Patents
Compoziţii şi metode de tratament al hepatitei virale CInfo
- Publication number
- MD4430C1 MD4430C1 MDA20140058A MD20140058A MD4430C1 MD 4430 C1 MD4430 C1 MD 4430C1 MD A20140058 A MDA20140058 A MD A20140058A MD 20140058 A MD20140058 A MD 20140058A MD 4430 C1 MD4430 C1 MD 4430C1
- Authority
- MD
- Moldova
- Prior art keywords
- virus
- compositions
- methods
- hepatitis
- treating hepatitis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Invenţia se referă la medicină, şi anume la farmacologie şi boli infecţioase, în special la compoziţii şi forme medicamentoase standardizate pentru tratamentul hepatitei virale C.Compoziţia farmaceutică conţine:a) circa 25% până la circa 35% m/mde formă cristalină cu structura:(GS-7977); şib) cel puţin un excipient acceptabil farmaceutic,unde valorile unghiului de reflexie 2Θ (°) ale formei cristaline GS-7977 determinate prin metoda XRPD sunt aproximativ: 6,1 şi 12,7.Conform invenţiei, de asemenea, sunt dezvăluite metode de tratare a pacienţilor cu hepatită virală C, care includ administrarea pentru o perioadă anumită de timp a unor cantităţi eficiente de GS-7977 şi de ribavirină fără interferon.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161564500P | 2011-11-29 | 2011-11-29 | |
PCT/US2012/055621 WO2013040492A2 (en) | 2011-09-16 | 2012-09-14 | Methods for treating hcv |
US201261707459P | 2012-09-28 | 2012-09-28 | |
US13/661,509 US20130109647A1 (en) | 2011-10-31 | 2012-10-26 | Methods and compositions for treating hepatitis c virus |
PCT/US2012/066605 WO2013082003A1 (en) | 2011-11-29 | 2012-11-27 | Compositions and methods for treating hepatitis c virus |
Publications (3)
Publication Number | Publication Date |
---|---|
MD20140058A2 MD20140058A2 (en) | 2014-11-30 |
MD4430B1 MD4430B1 (ro) | 2016-08-31 |
MD4430C1 true MD4430C1 (ro) | 2017-03-31 |
Family
ID=56291296
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MDA20140058A MD4430C1 (ro) | 2011-11-29 | 2012-11-27 | Compoziţii şi metode de tratament al hepatitei virale C |
Country Status (22)
Country | Link |
---|---|
EP (2) | EP2785340B1 (ro) |
JP (2) | JP5899327B2 (ro) |
KR (1) | KR101560994B1 (ro) |
CN (1) | CN104039319B (ro) |
AR (1) | AR089578A1 (ro) |
AU (1) | AU2012346217B2 (ro) |
BR (1) | BR112014012739A8 (ro) |
CA (1) | CA2856529C (ro) |
CO (1) | CO6970603A2 (ro) |
EA (1) | EA027296B1 (ro) |
EC (1) | ECSP14005678A (ro) |
ES (1) | ES2817886T3 (ro) |
HK (1) | HK1202268A1 (ro) |
MD (1) | MD4430C1 (ro) |
MX (1) | MX2014006373A (ro) |
PE (1) | PE20141296A1 (ro) |
PH (1) | PH12014501133A1 (ro) |
SG (1) | SG11201402609RA (ro) |
TW (1) | TWI566773B (ro) |
UY (1) | UY34474A (ro) |
WO (1) | WO2013082003A1 (ro) |
ZA (1) | ZA201404061B (ro) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ME03009B (me) | 2011-09-16 | 2018-10-20 | Gilead Pharmasset Llc | Metode za lecenje hcv-a |
JP2015508418A (ja) | 2013-01-31 | 2015-03-19 | ギリアド ファーマセット エルエルシー | 2種の抗ウイルス化合物のコンビナトリアル製剤 |
EP3113762A1 (en) * | 2014-03-05 | 2017-01-11 | Galenicum Health S.L. | Stable pharmaceutical compositions of sofosbuvir |
WO2015189386A1 (en) * | 2014-06-13 | 2015-12-17 | Teva Pharmaceuticals International Gmbh | Composition with a high drug load of sofosbuvir |
EA201692515A1 (ru) * | 2014-06-23 | 2017-05-31 | Сановель Илач Санайи Ве Тиджарет А.Ш. | Новая фармацевтическая композиция на основе софосбувира и рибавирина |
EA201692507A1 (ru) * | 2014-06-23 | 2017-04-28 | Сановель Илач Санайи Ве Тиджарет А.Ш. | Фармацевтические комбинации софосбувира и рибавирина |
EP2959891A1 (en) * | 2014-06-23 | 2015-12-30 | Sanovel Ilac Sanayi ve Ticaret A.S. | Modified release pharmaceutical compositions of sofosbuvir and ribavirin |
CN105267232A (zh) * | 2014-06-30 | 2016-01-27 | 康普药业股份有限公司 | 一种用于治疗丙型肝炎的药物制剂及其制备方法 |
WO2016035006A1 (en) * | 2014-09-01 | 2016-03-10 | Dr. Reddy’S Laboratories Limited | Novel nucleotide analogs, process for the preparation of sofosbuvir and its analogs, novel forms of sofosbuvir and solid dispersion of sofosbuvir |
US20170296570A1 (en) * | 2014-10-08 | 2017-10-19 | Sandoz Ag | High Drug Load Tablets Comprising Sofosbuvir |
CN104546783A (zh) * | 2014-12-12 | 2015-04-29 | 安徽一灵药业有限公司 | 一种索非布韦薄膜包衣片制剂及其制备方法 |
CN104622836B (zh) * | 2014-12-23 | 2020-02-21 | 浙江华海药业股份有限公司 | 索非布韦包衣片剂及其制备方法 |
HRP20211456T1 (hr) | 2014-12-26 | 2021-12-24 | Emory University | Protuvirusni derivati n4-hidroksicitidina |
CN104586802B (zh) * | 2015-02-02 | 2018-01-16 | 长春海悦药业股份有限公司 | 一种含有索菲布韦的药物组合物 |
WO2016156330A1 (en) * | 2015-03-30 | 2016-10-06 | Ratiopharm Gmbh | Solid pharmaceutical composition comprising amorphous sofosbuvir and a phospholipid |
CN104840964B (zh) * | 2015-05-07 | 2018-01-16 | 南京正大天晴制药有限公司 | 一种稳定的索氟布韦药物组合物及其制备方法 |
CZ2015443A3 (cs) | 2015-06-26 | 2017-01-04 | Zentiva, K.S. | Farmaceutická formulace sofosbuviru |
CN104906062B (zh) * | 2015-06-30 | 2018-05-25 | 浙江天顺生物科技有限公司 | 一种索非布韦的片剂及其制备方法 |
BR102017011025A2 (pt) | 2016-06-02 | 2017-12-19 | Gilead Pharmasset Llc | Formulation of combination of three antiviral compounds |
CN109843900A (zh) | 2016-08-19 | 2019-06-04 | 桑多斯股份公司 | 治疗丙型肝炎的索非布韦衍生物 |
CZ2016553A3 (cs) | 2016-09-09 | 2018-03-21 | Zentiva, K.S. | Pevná farmaceutická dávková forma obsahující sofosbuvir |
CN106667936B (zh) * | 2016-12-31 | 2021-02-05 | 江苏科本药业有限公司 | 一种索非布韦片剂及其制备方法 |
CN106880642B (zh) * | 2017-02-17 | 2019-08-06 | 杭州青玥医药科技有限公司 | 索氟布韦药物组合物及其制备方法 |
CN107041873B (zh) * | 2017-02-17 | 2020-02-28 | 杭州青玥医药科技有限公司 | 索氟布韦包衣片剂的制备方法 |
JP6804790B1 (ja) | 2017-12-07 | 2020-12-23 | エモリー ユニバーシティー | N4−ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途 |
KR20200043618A (ko) * | 2018-10-18 | 2020-04-28 | 주식회사유한양행 | 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물 |
CN110604726B (zh) * | 2019-07-19 | 2022-06-07 | 株洲千金药业股份有限公司 | 一种索非布韦组合物及其应用 |
CN111072742B (zh) * | 2019-12-23 | 2022-12-02 | 南京正大天晴制药有限公司 | 一种治疗丙肝药物的新晶型及其组合物 |
CN111973566A (zh) * | 2020-07-23 | 2020-11-24 | 石药集团中奇制药技术(石家庄)有限公司 | 一种索磷布韦片 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102008057284A1 (de) * | 2008-11-14 | 2010-05-20 | Ratiopharm Gmbh | Tabletten enthaltend Lenalidomid und Adhäsionsverstärker |
WO2010112203A1 (de) * | 2009-03-31 | 2010-10-07 | Ratiopharm Gmbh | Tabletten enthaltend dapoxetin und trockenverarbeitungsverfahren zu deren herstellung |
US20100267785A1 (en) * | 2007-10-30 | 2010-10-21 | Huahai Zhejiang Huahai Pharmaceutical Co., Ltd. | Candesartan cilexetil |
US20100298257A1 (en) * | 2009-05-20 | 2010-11-25 | Pharmasset, Inc. | Nucleoside phosphoramidates |
US20110251152A1 (en) * | 2009-05-20 | 2011-10-13 | Pharmasset, Inc. | Nucleoside phosphoramidates |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
IL154306A0 (en) * | 2003-02-05 | 2003-09-17 | Rimonyx Pharmaceuticals Ltd | Pharmaceutical compositions comprising thieno [2,3-c] pyridine derivatives and use thereof |
US7816326B2 (en) * | 2004-02-27 | 2010-10-19 | Schering Corporation | Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease |
US8435984B2 (en) * | 2007-02-26 | 2013-05-07 | Achillion Pharmaceuticals, Inc. | Tertiary amine substituted peptides useful as inhibitors of HCV replication |
US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
NZ583825A (en) * | 2007-09-14 | 2012-06-29 | Schering Corp | Method of treating hepatitis C patients comprising an HCV protease inhibitor, an antiviral compound and an interferon |
CA2743912A1 (en) * | 2008-11-20 | 2010-05-27 | Achillion Pharmaceuticals, Inc. | Cyclic carboxamide compounds and analogues thereof as of hepatitis c virus |
EP2467144A1 (en) * | 2009-07-24 | 2012-06-27 | ViroLogik GmbH | Combination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis |
PT3290428T (pt) | 2010-03-31 | 2021-12-27 | Gilead Pharmasset Llc | Comprimido compreendendo 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihidropirimidin-1-(2h)-il)¿4¿fluoro¿3¿hidroxi¿4¿metiltetrahidrofuran¿2¿il)metoxi) (fenoxi)fosforil)amino)propanoato de (s)- isopropil cristalino |
US20120107278A1 (en) | 2010-10-29 | 2012-05-03 | Pharmasset, Inc. | Abbreviated hcv therapy for hcv infected patients with il28b c/c genotype |
-
2012
- 2012-11-27 ES ES12795307T patent/ES2817886T3/es active Active
- 2012-11-27 WO PCT/US2012/066605 patent/WO2013082003A1/en active Application Filing
- 2012-11-27 BR BR112014012739A patent/BR112014012739A8/pt not_active Application Discontinuation
- 2012-11-27 EP EP12795307.3A patent/EP2785340B1/en active Active
- 2012-11-27 AU AU2012346217A patent/AU2012346217B2/en active Active
- 2012-11-27 CN CN201280058114.0A patent/CN104039319B/zh active Active
- 2012-11-27 JP JP2014543607A patent/JP5899327B2/ja active Active
- 2012-11-27 EP EP20176183.0A patent/EP3777867A1/en not_active Withdrawn
- 2012-11-27 MD MDA20140058A patent/MD4430C1/ro active IP Right Grant
- 2012-11-27 KR KR1020147016699A patent/KR101560994B1/ko active IP Right Grant
- 2012-11-27 CA CA2856529A patent/CA2856529C/en active Active
- 2012-11-27 SG SG11201402609RA patent/SG11201402609RA/en unknown
- 2012-11-27 PE PE2014000749A patent/PE20141296A1/es active IP Right Grant
- 2012-11-27 EA EA201490903A patent/EA027296B1/ru unknown
- 2012-11-27 MX MX2014006373A patent/MX2014006373A/es unknown
- 2012-11-28 TW TW101144495A patent/TWI566773B/zh active
- 2012-11-28 UY UY0001034474A patent/UY34474A/es active IP Right Grant
- 2012-11-29 AR ARP120104483A patent/AR089578A1/es not_active Application Discontinuation
-
2014
- 2014-05-21 PH PH12014501133A patent/PH12014501133A1/en unknown
- 2014-05-30 ZA ZA2014/04061A patent/ZA201404061B/en unknown
- 2014-06-05 CO CO14121393A patent/CO6970603A2/es not_active Application Discontinuation
- 2014-06-18 EC ECIEPI20145678A patent/ECSP14005678A/es unknown
-
2015
- 2015-03-19 HK HK15102826.9A patent/HK1202268A1/xx unknown
-
2016
- 2016-01-19 JP JP2016007633A patent/JP2016053096A/ja not_active Withdrawn
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100267785A1 (en) * | 2007-10-30 | 2010-10-21 | Huahai Zhejiang Huahai Pharmaceutical Co., Ltd. | Candesartan cilexetil |
DE102008057284A1 (de) * | 2008-11-14 | 2010-05-20 | Ratiopharm Gmbh | Tabletten enthaltend Lenalidomid und Adhäsionsverstärker |
WO2010112203A1 (de) * | 2009-03-31 | 2010-10-07 | Ratiopharm Gmbh | Tabletten enthaltend dapoxetin und trockenverarbeitungsverfahren zu deren herstellung |
US20100298257A1 (en) * | 2009-05-20 | 2010-11-25 | Pharmasset, Inc. | Nucleoside phosphoramidates |
US20110251152A1 (en) * | 2009-05-20 | 2011-10-13 | Pharmasset, Inc. | Nucleoside phosphoramidates |
Non-Patent Citations (4)
Title |
---|
Jacobson I.M. et al. Telaprevir for previously untreated chronic hepatitis C virus infection. New Engl.J. Med. 2011, nr. 364, p. 2405-2416 * |
Manns M.P. et al. Liver Int,l. 2012, p. 27-31 * |
Missiha S.B. et al. Gastroenterology. 2008, nr. 134, p. 1699-1714 * |
Naggie S.et.al. Hepatitis C virus directly acting antivirals: current developments with NS3/4A HCV serine protease inhibitors. J.Antimicrob. Chemother. 2010, nr. 65, p. 2063-2069 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MD4430C1 (ro) | Compoziţii şi metode de tratament al hepatitei virale C | |
HRP20180237T4 (hr) | Metode za liječenje hcv-a | |
DOP2011000343A (es) | Derivados de piridina tieno [2,3-b] como inhibidores de replicacion viral | |
MX2022013596A (es) | Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico. | |
MX2012007410A (es) | Compuestos antivirales novedosos. | |
PH12015501276A1 (en) | Functionalized benzamide derivatives as antiviral agents against hbv infection | |
TN2013000421A1 (en) | 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases | |
WO2009123776A3 (en) | Antiviral drugs for treatment of arenavirus infection | |
IL207468A (en) | HCV inhibitors and their use in the preparation of medicines for the treatment of HCV infections | |
WO2012142093A3 (en) | 2'-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases | |
MY202109A (en) | Viral replication inhibitors | |
NZ606993A (en) | Combination pharmaceutical composition and methods of treating and preventing the infectious diseases | |
MY180145A (en) | Cenicriviroc compositions and methods of making and using the same | |
MX2014002171A (es) | Tratamientos de combinacion para hepatitis c. | |
BR112015010396A2 (pt) | terapia de combinação | |
MX2012008652A (es) | Terapias para tratar infeccion por virus de hepatitis c. | |
EA201290556A1 (ru) | Оральная лекарственная форма, включающая энтекавир | |
MX2022006742A (es) | Uso y composicion farmaceutica de derivados de fenilisoxazolil metilen-naftaleno-eter. | |
MX2012004409A (es) | Proteina recombinante de humano cc10 para el tratamiento de la influenza. | |
MX2013003523A (es) | Composicion farmaceutica de dosis baja. | |
RU2013120345A (ru) | Новые способы лечения инфекции, вызванной вирусом гепатита с | |
MX2009006311A (es) | Terapia de combinacion para tratar infecciones de hepatitis c. | |
RU2013129824A (ru) | Новое лечение инфекции вируса гепатита с | |
MD3121G2 (ro) | Metodă de profilaxie a hepatitei virale B | |
EP2606885A4 (en) | "RENESSANS" MEDICINAL PREPARATION WITH ANTIBACTERIAL, ANTI-ULCER AND IMMUNOMODULATORY ACTION |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG4A | Patent for invention issued |